Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasson, Michael H., Ali, Mahmoud, De Oliveira, Vanessa, Xiao, Qian, Jethava, Yogesh, Zhan, Fenghuang, Fitzsimmons, Adam M., Bates, Melissa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274834/
https://www.ncbi.nlm.nih.gov/pubmed/30453544
http://dx.doi.org/10.3390/ijms19113621
_version_ 1783377699233857536
author Tomasson, Michael H.
Ali, Mahmoud
De Oliveira, Vanessa
Xiao, Qian
Jethava, Yogesh
Zhan, Fenghuang
Fitzsimmons, Adam M.
Bates, Melissa L.
author_facet Tomasson, Michael H.
Ali, Mahmoud
De Oliveira, Vanessa
Xiao, Qian
Jethava, Yogesh
Zhan, Fenghuang
Fitzsimmons, Adam M.
Bates, Melissa L.
author_sort Tomasson, Michael H.
collection PubMed
description Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study.
format Online
Article
Text
id pubmed-6274834
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62748342018-12-15 Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma Tomasson, Michael H. Ali, Mahmoud De Oliveira, Vanessa Xiao, Qian Jethava, Yogesh Zhan, Fenghuang Fitzsimmons, Adam M. Bates, Melissa L. Int J Mol Sci Review Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study. MDPI 2018-11-16 /pmc/articles/PMC6274834/ /pubmed/30453544 http://dx.doi.org/10.3390/ijms19113621 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tomasson, Michael H.
Ali, Mahmoud
De Oliveira, Vanessa
Xiao, Qian
Jethava, Yogesh
Zhan, Fenghuang
Fitzsimmons, Adam M.
Bates, Melissa L.
Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title_full Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title_fullStr Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title_full_unstemmed Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title_short Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
title_sort prevention is the best treatment: the case for understanding the transition from monoclonal gammopathy of undetermined significance to myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274834/
https://www.ncbi.nlm.nih.gov/pubmed/30453544
http://dx.doi.org/10.3390/ijms19113621
work_keys_str_mv AT tomassonmichaelh preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT alimahmoud preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT deoliveiravanessa preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT xiaoqian preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT jethavayogesh preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT zhanfenghuang preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT fitzsimmonsadamm preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma
AT batesmelissal preventionisthebesttreatmentthecaseforunderstandingthetransitionfrommonoclonalgammopathyofundeterminedsignificancetomyeloma

Ejemplares similares